Activated Cdc42-associated kinase or ACK, is a non-receptor tyrosine kinase and an effector protein for the small G protein Cdc42. A substantial body of evidence has accumulated in the past few years heavily implicating ACK as a driver of oncogenic processes. Concomitantly, more is also being revealed regarding the signalling pathways involving ACK and molecular details of its modes of action. Some details are also available regarding the regulatory mechanisms of this kinase, including activation and regulation of its catalytic activity, however, a full understanding of these aspects remains elusive. This review considers the current knowledge base concerning ACK and summarizes efforts and future prospects to target ACK therapeutically in cancer.
Skip Nav Destination
Article navigation
December 2019
-
Cover Image
Cover Image
The second messenger 3′,5′-cyclic nucleoside adenosine monophosphate (cAMP) plays a key role in signal transduction across prokaryotes and eukaryotes. In this issue Klausen and colleagues (1733–1748) provide an overview about the optogenetic tools and biosensors used to explore the subcellular organization of cAMP signalling. The cover image depicts time projection (colour represents time) of a head-tethered transgenic mouse sperm expressing the photo-activated adenylate cyclase bPAC. Image courtesy of Dagmar Wachten.
Review Article|
December 17 2019
The non-receptor tyrosine kinase ACK: regulatory mechanisms, signalling pathways and opportunities for attACKing cancer
Biochem Soc Trans (2019) 47 (6): 1715–1731.
Article history
Received:
October 08 2019
Revision Received:
November 30 2019
Accepted:
December 03 2019
 |
 |
